JNJ-56021927

· Aragon Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for JNJ-56021927, covering 2016-10-20 to 2026-06-05. Get the full timeline:

Most recent: Clinical Trial Update: An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS [Phase 3]

See pricing